$NUOT...catalyst, I am buying for a couple reason here today. First, the company Q4 call is at the end of the month. The last quarterly call the stock made a nice run into the event. .30 cents would be 20% gain.
I really like the management team, businesses execution strategy AND the entry and current valuation. That is very hard to find in today's biotech land. NUOT in my view has been overlooked. Coverage by Jason Napodano at Zacks who in my view is great at finding overlooked stories.
Two products we should get updates on. Angel which is now being sold by Atherex. Looking at Atherax website, they have incorporated Angel into a larger product portfolio and new marketing campaign. Atherax should easily be able to deliver better numbers to NUOT then the company was able to do on their own. I see a revenue beat on Angel sales or we see guidance that beats street expectation. NUOT mkt cap of 31m with 15m cash. Angel is worth at least 30M on its own, so you are getting their core value driver (product 2) for free, AURIX
AURIX was launched in October 2014' so we should get some early color on the launch and hopefully guidance for Q1 or some discussion on 2015 business goals.
Management is solid with excellent experience and success in the wound care market. They know how to operate and grow in this market with proven track record.
Napodano has a $1.40 price target or almost 6x from here. You can search his blog for a much deeper DD dive.
Similar to TTNP in that it should be a good longer term 2015 stock or play for run back into the .30's. CFO purchased shares last summer in the .34+ range.
-BioHunter
AI
